Table 4.
Pharmacokinetics of the different glycopeptides after multiple-dose administration in healthy individuals
| Name | Dose (mg) | Administration | N | Cmax (mg/L) | AUC∞ (mg·h/L) | AUC24 (mg·h/L) | t½ (h) | CLtotal | Clss (mL/h/kg) | VSS (mL/kg) | References | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (mL/min/kg) | (mL/min) | |||||||||||
| Telavancin | 10 mg/kg | od, 3 days, IV | 20 | 116 ± 30 | 862.8 cal | 785 ± 111 | 7.41 ± 1.08 | 13.0 ± 1.9 | 122 ± 22 | [40] | ||
| Dalbavancin | 1000 LD, 500 MD | ow, 2 weeks, IV | 9 | 278.3 ± 52.6 | 33,851 ± 8184 | 321 ± 24 | 0.783 ± 0.183 | 213.5cal | [41] | |||
| Oritavancin | 200 | od, 3 days, IV | 8 | 46.2 ± 10.7 | 457 ± 99.4 | [36] | ||||||
| Vancomycin | 500 | qd, 5 doses, IV | 11 | 40.3 ± 6.2 | 8.1 ± 2.2 | 84.8 ± 11.5a | 588 ± 130 | [43] | ||||
| Vancomycin | 1000 | bid, 3 doses, IV | 11 | 65.7 ± 7.9 | 7.7 ± 1.8 | 86.1 ± 8.9a | 587 ± 40 | |||||
| Teicoplanin | 6 mg/kg | bid 1 day, then od for 13 days | 9 | 159 | 0.203 | 1380 | [42] | |||||
| Teicoplanin | 12 mg/kg | bid 1 day, then od for 13 days | 7 | 155 | 0.233 | 1180 | ||||||
AUC area under the concentration–time curve, AUC24 AUC from time zero to 24 h, AUC∞ AUC from time zero to infinity, bid twice daily, cal value calculated using common pharmacokinetic equations, CLtotal apparent total body clearance, CLss CLtotal in steady state, Cmax maximum plasma concentration, IV intravenous, LD loading dose, MD maintenance dose, N number of subjects, od once daily, ow once weekly, t½ elimination half-life, Vss volume of distribution in steady state
amL/min/1.73 m2